論文

査読有り
2018年

Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity

Oncotarget
  • Kuan Chai
  • Xuerao Ning
  • Tho Thi Thanh Nguyn
  • Boya Zhong
  • Takao Morinaga
  • Zhihan Li
  • Masato Shingyoji
  • Yuji Tada
  • Koichiro Tatsumi
  • Hideaki Shimada
  • Kenzo Hiroshima
  • Naoto Yamaguchi
  • Masatoshi Tagawa
  • 全て表示

9
40
開始ページ
26130
終了ページ
26143
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.18632/oncotarget.25452
出版者・発行元
Impact Journals LLC

Heat shock protein 90 (HSP90) inhibitors suppressed MDM4 functions which mediated p53 ubiquitination, and blocked a chaperon function which influenced expression of the client proteins. We examined cytotoxic effects of the inhibitors, 17-allylamino-17-demetheoxygeldanamycin (17-AAG) and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17-DMAG), on mesothelioma and investigated combinatory effects of the inhibitors and adenoviruses expressing the wild-type p53 gene (Ad-p53). A majority of mesothelioma lacks p14 and p16 expression, which leads to defective p53 pathway despite bearing the wild-type p53 genotype. The HSP90 inhibitors up-regulated endogenous wild-type p53 expression and induced cell death. Furthermore, the inhibitors increased the endogenous p53 levels that were induced by cisplatin. Nevertheless, the HSP90 inhibitors suppressed Ad-p53-induced exogenous p53 expression primarily at a posttranscriptional level and inhibited the Ad-p53-mediated cell death. HSP90 inhibitors suppressed ubiquitination processes which were involved in p53 degradation, but a proteasome inhibitor, MG- 132, prevented the HSP90 inhibitors-induced p53 down-regulation. In contrast, an inhibitor for HSP70 with a chaperon function, pifithrin-μ, did not produce the p53 down-regulation. The HSP90 inhibitors did not suppress expression of Ad receptor molecules but rather increased expression of green fluorescence protein transduced by the same Ad vector. These data collectively indicated that an HSP90 inhibitor possessed a divalent action on p53 expression, as an activator for endogenous wildtype p53 through inhibited ubiquitination and a negative regulator of exogenously over-expressed p53 through the proteasome pathway.

リンク情報
DOI
https://doi.org/10.18632/oncotarget.25452
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29899847
ID情報
  • DOI : 10.18632/oncotarget.25452
  • ISSN : 1949-2553
  • PubMed ID : 29899847
  • SCOPUS ID : 85047462327

エクスポート
BibTeX RIS